| Item Type | Name |
|
Concept
|
Antigen Presentation
|
|
Concept
|
Receptors, Antigen, T-Cell, alpha-beta
|
|
Concept
|
Receptors, Antigen, T-Cell
|
|
Concept
|
Receptor-CD3 Complex, Antigen, T-Cell
|
|
Concept
|
Antigen-Presenting Cells
|
|
Concept
|
B7-1 Antigen
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Receptors, Antigen, B-Cell
|
|
Concept
|
HLA-A2 Antigen
|
|
Academic Article
|
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
|
|
Academic Article
|
Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
|
|
Academic Article
|
Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo.
|
|
Academic Article
|
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
|
|
Academic Article
|
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.
|
|
Academic Article
|
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
|
|
Academic Article
|
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
|
|
Academic Article
|
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
|
|
Academic Article
|
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.
|
|
Academic Article
|
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
|
|
Academic Article
|
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.
|
|
Academic Article
|
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
|
|
Academic Article
|
IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay
|
|
Academic Article
|
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
|
|
Academic Article
|
Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
|
|
Academic Article
|
IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.
|
|
Academic Article
|
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
|
|
Academic Article
|
CAR T-Cell Therapy in Large B-Cell Lymphoma.
|
|
Academic Article
|
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
|
|
Academic Article
|
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
|
|
Academic Article
|
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
|
|
Academic Article
|
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
|
|
Academic Article
|
The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
|
|
Academic Article
|
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
|
|
Academic Article
|
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
|
|
Academic Article
|
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
|
|
Academic Article
|
CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity.
|
|
Concept
|
MART-1 Antigen
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
CTLA-4 Antigen
|
|
Academic Article
|
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.
|
|
Academic Article
|
Managing the toxicities of CAR T-cell therapy.
|
|
Academic Article
|
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
|
|
Academic Article
|
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
|
|
Academic Article
|
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
|
|
Academic Article
|
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
|
|
Academic Article
|
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
|
|
Academic Article
|
A CAR against CAR for unintended consequences.
|
|
Academic Article
|
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy toxicities.
|
|
Academic Article
|
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
|
|
Academic Article
|
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy.
|
|
Academic Article
|
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.
|
|
Academic Article
|
How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies.
|
|
Academic Article
|
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
|
|
Academic Article
|
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
|
|
Academic Article
|
CAR-T failure: beyond antigen loss and T cells.
|
|
Academic Article
|
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
|
|
Academic Article
|
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
|
|
Academic Article
|
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
|
|
Academic Article
|
CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
|
|
Academic Article
|
Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy.
|
|
Academic Article
|
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
|
|
Academic Article
|
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
|
|
Academic Article
|
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
|
|
Academic Article
|
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.
|
|
Academic Article
|
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
|
|
Academic Article
|
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
|
|
Academic Article
|
CAR Treg cells: prime suspects in therapeutic resistance.
|
|
Academic Article
|
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
|
|
Academic Article
|
Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
|
|
Academic Article
|
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
|
|
Academic Article
|
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large?B-cell lymphoma.
|
|
Academic Article
|
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
|
|
Academic Article
|
Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation.
|
|
Academic Article
|
Prolonged cytopenia following CD19 CAR T?cell therapy is linked with bone marrow infiltration of clonally expanded IFN?-expressing CD8 T?cells.
|
|
Academic Article
|
A single-cell atlas of CD19 chimeric antigen receptor T?cells.
|
|
Academic Article
|
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
|
|
Academic Article
|
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
|
|
Academic Article
|
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
|
|
Academic Article
|
A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus.
|
|
Academic Article
|
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
|
|
Academic Article
|
CAR T-cell expansion: harmful or helpful?
|